HIV-I gene therapy: Promise for the future

Advances in Pharmacology

Volumn 49, Issue , 2000, Pages 229-261

  Dornburg, Ralph ^a   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY RNA; RIBOZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; ANIMAL MODEL; BIOLISTIC TRANSFORMATION; CLINICAL TRIAL; GENE THERAPY; GENE VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; REVIEW; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIGENS, CD4; BIOLISTICS; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HIV-1; HUMANS; MODELS, ANIMAL; RNA, ANTISENSE; RNA, CATALYTIC; VIRUS REPLICATION;

EID: 0034565008     PISSN: 10543589     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-3589(00)49029-0     Document Type: Article

References (171)

1. S. Agrawal Antisense oligonucleotides as antiviral agents Trends Bioctechnol. 10 1992 152 158
2. R.K. Akkina J.D. Rosenblatt A.G. Campbell I.S. Chen J.A. Zack Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse Blood 84 1994 1393 1398
3. W.F. Anderson Gene therapy for AIDS Hum. Gene Ther. 5 1994 149 150
4. I. Bahner K. Kearns Q.L. Hao E.M. Smogorzewska D.B. Kohn Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture J. Virol. 70 1996 4352 4360
5. I. Bahner K. Kearns Q.L. Hao E.M. Smogorzewska D.B. Kohn Transduction of human CD34(+) hematopoietic progenitor cells by a retroviral vector expressing an rre decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture J. Virol. 67 1996 3199 3207
6. I. Bahner C. Zhou X.J. Yu Q.L. Hao J.C. Guatelli D.B. Kohn Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes J. Virol. 67 1993 3199 3207
7. D. Baltimore Intracellular immunization Nature 235 1988 395 396
8. D. Baltimore The enigma of HIV infection Cell 82 1995 175 176
9. G. Bauer P. Valdez K. Kearns I. Bahner S.F. Wen J.A. Zaia D.B. Kohn Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes Blood 89 1997 2259 2267
10. M.A. Biasolo A. Radaelli L. Del Pup E. Franchin C. De Giuli-Morghen G. Palu A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection J. Virol. 70 1996 2154 2161
11. R.E. Bird K.D. Hardman J.W. Jacobson S. Johnson B.M. Kaufmann S.-M. Lee T. Lee S.H. Pope G.S. Riordan M. Whitlow Single-chain antigen-binding proteins Science 242 1988 423 426
12. R.M. Blaese Steps toward gene therapy. 2. Cancer and AIDS Hosp. Pract. 30 1995 37 45
13. M.L. Bonyhadi K. Moss A. Voytovich J. Auten C. Kalfoglou L. Plavec S. Forestell L. Su E. Bohnlein H. Kaneshima Revm10-expressing t cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication J. Virol. 71 1997 4707 4716
14. M. BouHamdan Y. Xue Y. Baudat B. Hu J. Sire R.J. Pomerantz L.X. Duan Diversity of HIV-1 vpr interactions involves usage of the wxxf motif of host cell proteins J. Biol. Chem. 273 1998 8009 8016
15. H.J. Brady C.G. Miles D.J. Pennington E.A. Dzierzak Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses Proc. Natl. Acad. Sci. USA 91 1994 365 369
16. S.H. Bridges N. Sarver Gene therapy and immune restoration for HIV disease Lancet 345 1995 427 432
17. M.B. Brother H.K. Chang J. Lisziewicz D. Su L.C. Murty B. Ensoli Block of tat-mediated transactivation of tumor necrosis factor beta gene expression by polymerictar decoys Virology 222 1996 252 256
18. G.L. Buchschacher E.O. Freed A.T. Panganiban Cells induced to express a human immunodeficiency virus type 1 envelope mutant inhibit the spread of the wildtype virus Hum. Gene Ther. 3 1992 391 397
19. M.L. Bukrinsky S. Haggerty M. Dempsey N. Sharova A. Adzhubel L. Spitz P. Lewis D. Goldfarb M. Emerman M. Stevenson A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells Nature 365 1993 666 670
20. B.A. Bunnell R.A. Morgan Gene therapy for aids Mol. Cells 6 1996 1 12
21. B.A. Bunnell R.A. Morgan Gene therapy for HIV infection Drugs Today 32 1996 209 224
22. L. Buonocore J.K. Rose Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat Proc. Natl. Acad. Sci. USA 90 1993 2695 2699
23. T.B. Campbell B.A. Sullenger Alternative approaches for the application of ribozymes as gene therapies for retroviral infections Adv. Pharmacol. 33 1995 143 178
24. A. Caputo M.P. Grossi R. Bozzini C. Rossi M. Betti P.C. Marconi G. Barbantibrodano P.G. Balboni Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region Gene Ther. 3 1996 235 245
25. A. Caputo C. Rossi R. Bozzini M. Betti M.P. Grossi G. Barbanti-Brodano P.G. Balboni Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication Gene Ther. 4 1997 288 295
26. A. Cara S.M. Rybak D.L. Newton R. Crowley S.E. Rottschafer M.S. Reitz Jr G.L. Gusella Inhibition of HIV-1 replication by combined expression of Gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector Gene Ther. 5 1998 65 75
27. M. Caruso D. Klatzmann Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population Proc. Natl. Acad. Sci. USA 89 1992 182 186
28. M. Caruso Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase Mol. Med. Today 2 1996 212 217
29. D. Castanotto J.J. Rossi N. Sarver Antisense catalytic RNAs as therapeutic agents Adv. Pharmacol. 25 1994 289 317
30. J.Y. Cesbron H. Agut B. Gosselin D. Candotti M. Raphael F. Puech M. Grandadam P. Debre A. Capron B. Autran SCID-hu mouse as a model for human lung HIV-1 infection C. R. Acad. Sci. III 317 1994 669 674
31. H.K. Chang R. Gendelman J. Lisziewicz R.C. Gallo B. Ensoli Block of HIV-1 infection by a combination of antisense tat RNA and Tar decoys: A strategy for control of HIV-1 Gene Ther. 1 1994 208 216
32. I.S. Chen J.A. Zack Modeling human retroviral pathogenesis and antiretroviral gene therapy in the scid mouse Res. Immunol. 145 1994 385 392
33. S.Y. Chen J. Bagley W.A. Marasco Intracellular antibodies as a new class of therapeutic molecules for gene therapy Hum. Gene Ther. 5 1994 595 601
34. S.Y. Chen Y. Khouri J. Bagley W.A. Marasco Combined intra-and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody Proc. Natl. Acad. Sci. USA 91 1994 5932 5936
35. T.-H. Chu R. Dornburg Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer J. Virol. 69 1995 2659 2663
36. T.-H. Chu R. Dornburg Towards highly-efficient cell-type-specific gene transfer with retroviral vectors that display a single chain antibody J. Virol 71 1997 720 725
37. T.-H. Chu L. Martinez W.C. Sheay R. Dornburg Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins Gene Ther. 1 1994 292 299
38. M.K. Chuah T. Vandendriessche H.K. Chang B. Ensoli R.A. Morgan Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-Tar Hum. Gene Ther. 5 1994 1467 1475
39. T.W. Chun L. Stuyver S.B. Mizell L.A. Ehler J.A. Mican M. Baseler A.L. Lloyd M.A. Nowak A.S. Fauci Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc. Natl. Acad. Sci. 94 1997 13193 13197
40. J.S. Cohen Antisense oilgonucleotides as antiviral agents Antiviral Res. 16 1991 121 133
41. J. Cohen Gene therapy-new role for HIV—A vehicle for moving genes into cells Science 272 1996 195
42. T.J. Curiel D.R. Cook Y. Wang B.H. Hahn S.K. Ghosh G.S. Harrison Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin a chain gene Hum. Gene. Ther. 4 1993 741 747
43. E. de Clercq Non-nucleoside reverse transcriptase inhibitors (nnrtis) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development Med Res Rev 16 1996 125 157
44. J.E. Dick Immune-deficient mice as models of normal and leukemic human hematopoiesis Cancer Cells 3 1991 39 48
45. J.E. Dick C. Sirard F. Pflumio T. Lapidot Murine models of normal and neoplastic human haematopoiesis Cancer Surv. 15 1992 161 181
46. J.E. Dick Future prospects for animal models created by transplanting human haematopoietic cells into immune-deficient mice Res. Immunol. 145 1994 380 384
47. M.M. Dinges D.R. Cook J. King T.J. Curiel X.Q. Zhang G.S. Harrison HIV-regulated diphtheria toxin a chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line u937 Hum. Gene Ther. 6 1995 1437 1445
48. M.M. Dinges D.R. Cook J. King T.J. Curie] X.Q. Zhang G.S. Harrison HIV-regulated diphtheria toxin a chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937 Hum. Gene Ther. 6 1995 1437 1445
49. R.E. Donahue B.A. Bunnell M.C. Zink M.E. Metzger R.P. Westro M.R. Kirby T. Unangst J.E. Clements R.A. Morgan Reduction in SIV replication in rhesus macaques infused with autologous lymphozytes engineered with antiviral genes Nat. Med. 4 1998 181 186
50. R. Dornburg Reticuloendotheliosis viruses and derived vectors Gene Ther. 2 1995 301 310
51. R. Dornburg From the natural evolution to the genetic manipulation of the host range of retroviruses Biol. Chem. 378 1997 457 468
52. J.P. Dougherty R. Wisniewski S. Yang B.W. Rhode H.M. Temin New retrovirus helper cells with almost no nucleotide sequence homology to retrovirus vectors J. Virol. 63 1989 3209 3212
53. B. Dropubic K.-T. Jeang Gene therapy for human immunodeficiency virus infection: Genetic antiviral strategies and targets for intervention Hum. Gene Ther. 5 1994 927 939
54. L. Duan R.J. Pomerantz Intracellular antibodies for HIV-1 gene therapy Sci. Med. 3 1996 24 36
55. L. Duan O. Bagasra M.A. Laughlin J.W. Oakes R.J. Pomerantz Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular antirev single-chain antibody Proc. Natl. Acad. Sci. USA 91 1994 5075 5079
56. L. Duan H. Zhang J.W. Oakes O. Bagasra R.J. Pomerantz Molecular and virological effects of intracellular anti-rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains Hum. Gene Ther. 5 1994 1315 1324
57. E.A. Duarte M.C. Leavitt O. Yamada M. Yu Hairpin ribozyme gene therapy for aids Methods Mol. Biol. 74 1997 459 468
58. T. Dull R. Zufferey M. Kelly R.J. Mandel M. Nguyen D. Trono L. Naldini A third-generation lentivirus vector with a conditional packaging system J. Virol. 72 1998 8463 8471
59. D.J. Earnshaw M.J. Gait Progress toward the structure and therapeutic use of the hairpin ribozyme Antisense Nucleic Acid Drug. Dev. 7 1997 403 411
60. M.A. Eglitis W.F. Anderson Retroviral vectors for introduction of genes into mammalian cells Biotechniques 6 1988 608 614
61. J.E. Embretson M. Zupanic J.L. Ribas A. Burke P. Racz K. Tenner-Racz A.T. Haase Massive covert infection of helper T lymphocytes and macrophages by HIV during incubation period of AIDS Nature 362 1993 359 362
62. J.W. Erickson S.K. Burt Structural mechanisms of HIV drug resistance Annu. Rev. Pharmacol. Toxicol. 36 1996 545 571
63. M. Etienne-Julan P. Roux S. Carillo P. Jeanteur M. Piechaczyk The efficiency of cell targeting by recombinant retroviruses depends on the nature opf the receptor and the composition of the artificial cell-virus linker J. Gen. Virol. 73 1992 3251 3255
64. D. Finzi M. Hermankova T. Pierson L.M. Carruth C. Buck R.E. Chaisson T.C. Quinn K. Chadwick J. Margolick R. Brookmeyer J. Gallant M. Markowitz D.D. Ho D.D. Richman R.F. Siliciano Identification of a reservoir for HIV1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
65. E.O. Freed E.L. Delwart G.L. Buchschacher A.T. Panganiban A mutation in the human immunodeficiency virus type 1 transmembrane glycosylation gp41 dominantly interferes with fusion and infectivity Proc. Natl. Acad. Sci. USA 89 1992 70 74
66. D. Fulcher K. Clezy Antiretroviral therapy Med. J. Aust. 164 1996 607
67. M.-C. Gauduin G.P. Allaway W.C. Olson R. Weir P.J. Maddon R.A. Koup CD4-immunogtobulin G2 protects hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates J. Virol. 72 1998 3475 3478
68. M.-C. Gauduin P.W.H.I. Parren R. Weir C.F. Barbas D.R. Burton R.A. Koup Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 Nat. Med. 3 1997 1389 1393
69. A. Gervaix X. Li G. Kraus F. Wong-Staal Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades J. Virol. 71 1997 3048 3053
70. A. Gervaix L. Schwarz P. Law A.D. Ho D. Looney T. Lane F. Wong-Staal Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals Hum. Gene Ther. 8 1997 2229 2238
71. E. Gilboa Retroviral gene transfer: Applications to human gene therapy Prog. Clin. Biol. Res. 352 1990 301 311
72. E. Gilboa C. Smith Gene therapy for infectious diseases: The AIDS model Trends Genet. 10 1994 139 144
73. W.H. Gunzburg B. Salmons Development of retroviral vectors as safe, targeted gene delivery systems J. Mol. Med. 74 1996 171 182
74. M. Hallek C.M. Wendmer Recombinant adeno-associated virus (raav) vectors for somatic gene therapy-Recent advances and potential clinical applications Cytokines Mol. Ther. 2 1996 69 79
75. A. Hampel The hairpin ribozyme: Discovery, two-dimensional model, and development for gene therapy Prog. Nucleic Acid Res. Mol. Biol. 58 1998 1 39
76. M. Heusch G. Kraus P. Johnson F. Wong-Staal Intracellular immunization against SfVmac utilizing a hairpin ribozyme Virology 216 1996 241 244
77. A.D. Ho X.Q. Li T.A. Lane M. Yu P. Law F. Wongstaal Stem cells as vehicles for gene therapy—Novel strategy for HIV infection Stem Cells 13 1995 100 105
78. E. Hunter R. Swanstrom Retrovirus envelope glycoproteins Curr. Top. Microbiol. Immunol. 157 1990 187 253
79. H. Ilves C. Barske U. Junker E. Bohnlein G. Veres Retroviral vectors designed for targeted expression of rna polymerase III-driven transcripts—A comparative study Gene 171 1996 203 208
80. B.D. Jamieson G.M. Aldrovandi J.A. Zack The SCID-hu mouse: An in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS Semin. Immunol. 8 1996 215 221
81. A. Jiang T.-H.T. Chu F. Nocken K. Cichutek R. Dornburg Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies J. Virol. 72 1998 10148 10156
82. A. Jiang R. Dornburg In vivo cell-type-specific gene delivery with retroviral vectors that display single chain antibodies Gene Ther. 6 1999 1982 1987
83. M.L. Johnston H.S. Allaudeen N. Sarver HIV proteinase as a target for drug action Trends Pharmacol. Sci. 10 1989 305 307
84. U. Junket J. Baker C.S. Kalfoglou G. Veres H. Kaneshima E. Bohnlein Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1 AIDS Res. Hum. Retroviruses 13 1997 1395 1402
85. J.C. Kaplan M.S. Hirsch Therapy other than reverse transcriptase inhibitors for HIV infection Clin. Lab. Med. 14 1994 367 391
86. M. Kaul H. Yu Y. Ron J.P. Dougherty Regulated Antiviral packaging cell line devoid of most viral cis-acting sequences Virology 249 1998 167 174
87. V.N. Kim K. Mitrophanous S.M. Kingsman A.J. Kingsman Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1 J. Virol. 72 1998 811 816
88. S. Larsson G. Hotchkiss J. Su T. Kebede M. Andang T. Nyholm B. Johnstnon A. Sonnerborg A. Vahlne S. Britton L. Ahrlund-Richter A novel ribozyme target site located in the HIV-1 nef open reading frame Virology 219 1996 161 169
89. M.C. Leavitt M. Yu O. Yamada G. Kraus D. Looney E. Poeschla F. Wong-Staal Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes Hum. Gene Ther. 5 1994 1115 1120
90. M.C. Leavitt M. Yu F. Wongstaal D.J. Looney Ex vivo transduction and expansion of CD4(+) lymphocytes from HIV+ donors—Prelude to a ribozyme gene therapy trial Gene Ther. 3 1996 599 606
91. S.W. Lee H.F. Gallardo E. Gilboa C. Smith Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain J. Virol. 68 1994 8254 8264
92. P. Lewis M. Emerman Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus J. Virol 68 1994 510 516
93. X. Li A. Gervaix D. Kang P. Law S.A. Spector A.D. Ho F. Wong-Staal Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: Preclinical studies Gene Ther. 5 1998 233 239
94. S.E. Liem A. Ramezani X. Li S. Joshi The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance Hum. Gene Ther. 4 1993 625 634
95. J. Lisziewicz D. Sun A. Lisziewicz R.C. Gallo Antitat gene therapy: A candidate for late-stage AIDS patients Gene Ther. 2 1995 218 222
96. J. Lisziewicz D. Sun J. Smythe P. Lusso F. Lori A. Louie P. Markham J. Rossi M. Reitz R.C. Gallo Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS Proc. Natl. Acad. Sci. USA 90 1993 8000 8004
97. J. Liu C. Woffendin Z.Y. Yang G.J. Nabel Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells Gene Ther. 1 1994 32 37
98. F. Lori J. Lisziewicz J. Smythe A. Cara T.A. Bunnag D. Curiel R.C. Gallo Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 Tat and Gag Gene Ther. 1 1994 27 31
99. S.D. Lyman K. Brasel A.M. Rousseau D.E. Williams The flt3 ligand: A hematopoietic stem cell factor whose activities are distinct from steel factor Stem Cells 12 Suppl. 1 1994 99 107
100. W.A. Marasco S. Chen J.H. Richardson U. Ramstedt S.D. Jones Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy Hum. Gene Ther. 9 1998 1627 1642
101. M. Marin D. Noel S. Valsesia-Wittman F. Brockly M. Etienne-Julan S. Russell F.-L. Cosset M. Piechaczyk Targeted infection of human cells via major histocompatibility complex class I molecules by Moleney leukemia virus-derived viruses displaying single chain antibody fragment-envelope fusion proteins J. Virol. 70 1996 2957 2962
102. T. Matano T. Odawara A. Iwamoto H. Yoshikura Targeted infection of a retrovirus bearing a CD4-env chimera into human cells expressing human immunodeficiency virus type 1 J. Gen. Virol. 76 1995 3165 3169
103. Z. Matsuda X. Yu Q.C. Yu T.H. Lee M. Essex A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1 Proc. Natl. Acad Sci. USA 90 1993 3544 3548
104. A. Michienzi L. Conti B. Varano S. Prislei S. Gessani I. Bozzoni Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line Hum. Gene Ther. 9 1998 621 628
105. A.D. Miller Retrovirus packaging cells Hum. Gene. Ther. 1 1990 5 14
106. K. Miyake N. Suzuki H. Matsuoka T. Tohyama T. Shimada Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells Hum. Gene Ther. 9 1999 467 475
107. H. Mochizuki J.P. Schwartz K. Tanaka R.O. Brady J. Reiser High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells J. Virol. 72 1998 8873 8883
108. R.A. Morgan W.F. Anderson Human gene therapy Annu. Rev. Biochem. 62 1993 191 217
109. R.A. Morgan G. Baler-Bitterlich J.A. Ragheb F. Wong-Staal R.C. Gallo W.F. Anderson Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: Demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1 AIDS Res. Hum. Retroviruses 10 1994 1507 1515
110. R.A. Morgan D.J. Looney D.D. Muenchau F. Wong-Staal R.C. Gallo W.F. Anderson Retroviral vectors expressing soluble CD4: A potential gene therapy for AIDS AIDS Res. Hum. Retroviruses 6 1990 183 191
111. B.M. Mueller R.A. Reisfeld Potential of the SCID mouse as a host for human tumors Cancer Metastasis Rev. 10 1991 193 200
112. N. Muzyczka Use of adeno-associated virus as a general transduction vector for mammalian cells Curr. Top. Microbiol. Immunol. 158 1992 97 129
113. L. Naldini U. Blomer F.H. Gage D. Trono I.M. Verma Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector Proc. Natl. Acad. Sci. USA 93 1996 11382 11388
114. B.H.K. Nilson F.J. Morling F.-L. Cosset S.J. Russell Targeting of retroviral vectors through protease-substrate interactions Gene Tber. 3 1996 280 286
115. G.P. Nolan Harnessing viral devices as pharmaceuticals: Fighting HIV-1's fire with fire Cell 90 1997 821 824
116. D. Orlic L.J. Girard C.T. Jordan S.M. Anderson A.P. Cline D.M. Bodine The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction Proc. Natl. Acad. Sci. USA 93 1996 11097 11102
117. G. Pantaleo C. Graziosi J.F. Demarest L. Butini M. Montroni C.H. Fox J.M. Orenstein D.P. Kotler A.S. Fauci HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease Nature 362 1993 355 358
118. C. Parolin J. Sodroski A defective HIV-1 vector for gene transfer to human lymphocytes J. Mol. Med. 73 1995 279 288
119. L. Plavec M. Agarwal K.E. Ho M. Pineda J. Auten J. Baker H. Matsuzaki S. Escaich M. Bonyhadi E. Bohnlein High transdominant revm10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implication for gene therapy of aids Gene Tber. 4 1997 128 139
120. E. Poeschla F. Wong-Staal Antiviral and anticancer ribozymes Curr. Opin. Oncol. 6 1994 601 606
121. E.M. Poeschla F. Wong-Staal Gene therapy and HIV disease AIDS Clin. Rev. 1995 1 45
122. R.J. Pomerantz D. Trono Genetic therapies for HIV infections: Promise for the future AIDS 9 1995 985 993
123. R.J. Pomerantz O. Bagasra D. Baltimore Cellular latency of human immunodeficiency virus type 1 Curr. Opin. Immunol. 4 1992 475 480
124. H.G. Purchase R.L. Witter The reticuloendotheliosis viruses Curr. Top. Microbiol. Immunol. 71 1975 103 124
125. L. Putman Debate grows on safety of gene-therapy vectors Lancet 351 1998 808
126. J.A. Ragheb P. Bressler M. Daucher L. Chiang M.K. Chuah T. Vandendriessche R.A. Morgan Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics AIDS Res. Hum. Retroviruses 11 1995 1343 1353
127. A. Ramezani S.F. Ding S. Joshi Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes Gene Ther. 4 1997 861 867
128. U. Ranga C. Woffendin S. Verma L. Xu C.H. June D.K. Bishop G.J. Nabel Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals Proc. Natl. Acad. Sci. USA 95 1998 1201 1206
129. U. Ranga C. Woffendin S. Verma L. Xu C.H. June D.K. Bishop G.J. Nabel Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals Proc. Natl. Acad. Sci. USA 95 1998 1201 1205
130. D. Richman HIV drug resistance AIDS Res. Hum. Retroviruses 8 1992 1065 1071
131. I.J. Rondon W.A. Marasco Intracellular antibodies (intrabodies) for gene therapy of infectious diseases Annu. Rev. Microbiol. 51 1997 257 283
132. C. Rossi P.G. Balboni M. Betti P.C. Marconi R. Bozzini M.P. Grossi G. Barbanti-Brodano A. Caputo Inhibition of HIV-1 replication by a tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients Gene Ther. 4 1997 1261 1269
133. J.J. Rossi N. Sarver Catalytic antisense RNA (ribozymes): Their potential and use as anti-HIV-1 therapeutic agents Adv. Exp. Med. Biol. 312 1992 95 109
134. M. Rothenberg G. Johnson C. Laughlin L. Green J. Cradock N. Sarver J.S. Cohen Oligodeoxynucleotides as anti-sense inhibitors of gene expression: Therapeutic implications J. Natl. Cancer Inst. 81 1989 1539 1544
135. P. Roux P. Jeanteur M. Piechaczyk A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses Proc. Natl. Acad. Sci. USA 86 1989 9079 9083
136. S.J. Russell R.E. Hawkins G. Winter Retroviral vectors displaying functional antibody fragments Nucleic Acid. Res. 21 1993 1081 1085
137. E. San Jose M.A. Munoz-Fernandez B. Alarcon Retroviral vector-mediated expression in primary human T cells of an endoplasmic reticulum-retained CD4 chimera inhibits human immunodeficiency virus type-1 replication Hum. Gene Ther. 9 1998 1345 1357
138. P.A. Sandstrom T.M. Folks New strategies for treating aids Bioessays 18 1996 343 346
139. N. Sarver J. Rossi Gene therapy: A bold direction for HIV-1 treatment AIDS Res. Hum. Retroviruses 9 1993 483 487
140. M.J. Schnell J.E. Johnson L. Buonocore J.K. Rose Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection Cell 90 1997 849 857
141. B.S. Schnierle D. Moritz M. Jeschke B. Groner Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles Gene Ther. 3 1996 334 342
142. U. Schwedler R.S. Kornbluth D. Trono The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes Proc. Natl. Acad. Sci. USA 91 1999 6992 6996
143. R.N. Shen L. Lu H.E. Broxmeyer New therapeutic strategies in the treatment of murine diseases induced by virus and solid tumors: Biology and implications for the potential treatment of human leukemia, aids, and solid tumors Crit. Rev. Oncol. Hematol. 10 1990 253 265
144. J.A. Sraythe D. Sun M. Thomson P.D. Markham M.S. Reitz Jr R.C. Gallo J. Lisziewicz A Rev-inducible mutant Gag gene stably transferred into T lymphocytes: An approach to gene therapy against human immunodeficiency virus type 1 infection Proc. Natl. Acad. Sci. USA 91 1994 3657 3661
145. N.V. Somia M. Zoppe I.M. Verma Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery Proc. Natl. Acad. Sci. USA 92 1995 7570 7574
146. C.A. Stein Y.C. Cheng Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science 261 1993 1004 1012
147. B.A. Sullenger H.F. Gallardo G.E. Ungers E. Gilboa Over-expression of TAR sequences renders cells resistant to HIV replication Cell 63 1990 601 608
148. S.M. Sullivan Development of ribozymes for gene therapy J. Invest. Dermatol. 103 1994 85S 89S
149. H.M. Temin Retrovirus vectors for gene transfer: Efficient integration into and expression of exogenous DNA in vertebrate cell genomes R. Kucherlapati Gene Transfer 1986 Plenum New York 144 187
150. D. Trono M.B. Feinberg D. Baltimore HIV-1 gag mutants can dominantly interfere with the replication of wild-type virus Cell 59 1988 113 120
151. N. Uchida R.E. Sutton A.M. Friera D. He M.J. Reitsma W.C. Chang G. Veres R. Scollay I.L. Weissman HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated g0/g1 human hematopoietic stem cells Proc. Natl. Acad. Sci. USA 95 1998 11939 11944
152. F.M. Uckun Severe combined immunodeficient mouse models of human leukemia Blood 88 1996 1135 1146
153. S. Valsesia-Wittmann F. Morling B. Nilson Y. Takeuchi S. Russell F.-L. Cosset Improvement of retroviral retargeting by using acid spacers between an additional binding domain and the N terminus of Moloney leukemia virus SU J. Virol. 70 1996 2059 2064
154. T. Vandendriessche M.K. Chuah L. Chiang H.K. Chang B. Ensoli R.A. Morgan Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes J. Virol. 69 1995 4045 4052
155. D. von Laer S. Thomsen B. Vogt M. Donath J. Kruppa A. Rein W. Ostertag C. Stocking Entry of amphotropic and 10a1 pseudotyped murine retroviruses is restricted in hematopoietic stem cell lines J. Virol. 72 1998 1424 1430
156. L. Wang C. Witherington A. King W.L. Gerlach A. Carr R. Penny D. Cooper G. Symonds L.Q. Sun Preclinical characterization of an anti-tat ribozyme for therapeutic application Hum. Gene Ther. 9 1998 1283 1291
157. J.F. Warner D. Jolly S. Mento J. Galpin R. Haubrich J. Merritt Retroviral vectors for HIV immunotherapy Ann. N.Y. Acad. Sci. 772 1995 105 116
158. M. Weerasinghe S.E. Liem S. Asad S.E. Read S. Joshi Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme J. Virol. 65 1991 5531 5534
159. M. Whitlow D. Filpula Single-chain Fv proteins and their fusion proteins Methods Enzymol. 2 1991 1 9
160. C. Woffendin U. Ranga Z.Y. Yang L. Xu G.J. Nabel Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients Proc. Natl. Acad. Sci. USA 93 1996 2889 2894
161. C. Woffendin Z.Y. Yang L. Udaykumar Xu N.S. Yang M.J. Sheehy G.J. Nabel Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells Proc. Natl. Acad. Sci. USA 91 1994 11581 11585
162. J.K. Wong M. Hezareh H.F. Gunthard D.V. Havlir C.C. Ignacio C.A. Spina D.D. Richman Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 278 1997 1291 1295
163. F. Wongstaal Ribozyme gene therapy for HIV infection-Intracellular immunization of lymphocytes and CD34+ cells with an anti-HIV-1 ribozyme gene Adv. Drug Deliv. Rev. 17 1995 363 368
164. X. Wu H. Liu H. Xiao J.A. Conway J.C. Kappes Inhibition of human and simian immunodeficiency virus protease function by targeting vpx-protease-mutant fusion protein into viral particles J. Virol. 70 1996 3378 3384
165. A.G. Yang X. Bai X.F. Huang C. Yao S. Chen Phenotypic knockout of HIV type 1 chemokine coreceptor ccr-5 by intrakines as potential therapeutic approach for HIV-1 infection Proc. Natl. Acad. Sci. USA 94 1997 11567 11572
166. J.A.T. Young P. Bates K. Willert H.E. Varmus Efficient incorporation of human CD4 protein into avian leukosis virus particles Science 250 1990 1421 1423
167. M. Yu J. Ojwang O. Yamada A. Hampel J. Rapapport D. Looney F. Wong-Staal A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 Proc. Natl. Acad. Sci. USA 90 1993 6340 6344
168. M. Yu E. Poeschla F. Wong-Staal Progress towards gene therapy for HIV infection Gene Ther. 1 1994 13 26
169. M. Yu E. Poeschla F. Wong-Staal Progress towards gene therapy for HIV infection Gene Ther. 1 1994 13 26
170. M. Yu E. Poeschla O. Yamada P. Degrandis M.C. Leavitt M. Heusch J.K. Yees F. Wong-Staal A. Hampel In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1 Virology 206 1995 381 386
171. H. Zhang G. Dornadula M. Beumont L. Livornese Jr B. Van Uitert K. Henning R.J. Pomerantz Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy N. Engl. J. Med. 339 1998 1803 1809